Hyun C. Chung

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 92 publications

Treatment patterns and clinical outcomes of metastatic gastric cancer in South Korea: real-world evidence from retrospective electronic medical records data.

Treatment patterns and clinical outcomes of metastatic gastric cancer in South Korea: real-world evidence from retrospective electronic medical records data.

Journal: BMC cancer

Published: December 26, 2025

Analytical and clinical validation of CancerMaster, an automated targeted NGS panel, for tumor-only precision oncology.

Analytical and clinical validation of CancerMaster, an automated targeted NGS panel, for tumor-only precision oncology.

Journal: Scientific reports

Published: October 15, 2025

Corrigendum to "Efficacy of the first-line immune checkpoint inhibitor plus chemotherapy for gastroesophageal cancer: A meta-analysis of phase III trials including unreported PD-L1 subgroups" [Cancer Lett. 623, (2025) 217718].

Corrigendum to "Efficacy of the first-line immune checkpoint inhibitor plus chemotherapy for gastroesophageal cancer: A meta-analysis of phase III trials including unreported PD-L1 subgroups" [Cancer Lett. 623, (2025) 217718].

Journal: Cancer letters

Published: June 04, 2025

Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer.

Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer.

Journal: European journal of cancer (Oxford, England : 1990)

Published: November 15, 2024

Pembrolizumab in HER2-Positive Gastric Cancer.

Pembrolizumab in HER2-Positive Gastric Cancer.

Journal: The New England journal of medicine

Published: September 16, 2024

Efficacy of the first-line immune checkpoint inhibitor plus chemotherapy for gastroesophageal cancer: A meta-analysis of phase III trials including unreported PD-L1 subgroups.

Efficacy of the first-line immune checkpoint inhibitor plus chemotherapy for gastroesophageal cancer: A meta-analysis of phase III trials including unreported PD-L1 subgroups.

Journal: Cancer letters

Published: September 10, 2024

Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.

Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.

Journal: Investigational new drugs

Published: May 20, 2024

Reply to B. Freidlin et al.

Reply to B. Freidlin et al.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 04, 2024

Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study.

Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study.

Journal: Gynecologic oncology

Published: January 25, 2024

Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.

Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.

Journal: The lancet. Gastroenterology & hepatology

Published: December 24, 2023

Varlitinib and Paclitaxel for EGFR/HER2 Co-expressing Advanced Gastric Cancer: A Multicenter Phase Ib/II Study (K-MASTER-13).

Varlitinib and Paclitaxel for EGFR/HER2 Co-expressing Advanced Gastric Cancer: A Multicenter Phase Ib/II Study (K-MASTER-13).

Journal: Cancer research and treatment

Published: December 17, 2023

Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple-negative breast cancer: Results from the triple-negative breast cancer cohort of the phase 2 LEAP-005 Study.

Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple-negative breast cancer: Results from the triple-negative breast cancer cohort of the phase 2 LEAP-005 Study.

Journal: Cancer

Published: December 07, 2023

Showing 1-12 of 92

Last Updated: 09/26/2026